Archives: Agenda

PANEL DISCUSSION Future of Clinical Trial Professionals: How Technology Is Transforming Workforce Roles and Expectations

  • Reimagining responsibilities across clinical trial functions in an AI- and automation-driven environment
  • Evolving from task-based roles to strategic, insight-driven contributors across operations and data functions
  • Redefining entry-level roles as technology reshapes foundational skills, expectations, and career pathways
  • Identifying the new capabilities required to ensure technology enhances, not replaces the expertise of clinical trial professionals

PANEL DISCUSSION Maximising Site Productivity: Infrastructure, Burden Reduction and Stronger Output in UK Clinical Trials

Robust, well supported site infrastructure is the foundation of efficient clinical trial delivery across the UK and Ireland. This session will examine how workforce, facilities, digital systems and governance structures at NHS and HSE sites can be optimised to reduce operational burden and increase throughput of high quality studies. Panellists will share practical strategies for investing in and partnering with sites to strengthen research infrastructure, streamline processes, and enable sustainable growth in commercial and academic trial activity.

  • Assessing current site infrastructure: workforce, facilities, governance and digital capabilities in NHS/HSE settings.
  • Targeted investments and partnerships that meaningfully strengthen site capacity and trial readiness.
  • Aligning sponsor/CRO expectations and processes with real site infrastructure constraints.
  • Building scalable, resilient site infrastructure that supports long term growth in UK & Irish clinical research.

Mind the Gap: Enhancing the Work of Regulatory Agencies through the Voluntary Adoption of International Quality Standards

All clinical research sites must be inspection-ready and compliant with regulations. Yet some choose to go further – voluntarily subjecting themselves to rigorous international accreditation and certification standards that exceed statutory obligations. What drives this commitment to excellence, and how does it strengthen resilience and quality to mitigate systemic risk?

 

In this session you will:

  • Gain insight into how global certification and accreditation standards are developed, governed and maintained
  • Understand the strategic role of voluntary independent quality standards in enhancing public trust, workforce engagement, and the delivery of effective clinical trials; enhancing the work of regulatory agencies
  •  Explore how certification enhances clinical research business systems, operational efficiency, and risk management
  • Hear real-world case studies from leading oncology research sites in the UK and internationally, demonstrating measurable impact on transparency, capability building, and organisational performance

The Future of RBQM for Early Phase Studies Starts Here

RBQM is essential for protecting patient safety and driving quality by design principles across all phases of clinical research and is arguably more important in early phase studies than any other. Yet in practice, the application of RBQM to early phase is highly inconsistent, often relying on manual processes and individual judgement instead of structured processes, supported by compliant technology.

In this session we’ll share where the gaps are in RBQM adoption and implementation, what’s at stake when sponsors get this wrong, as well as how to move forward to implement a rigorous RBQM strategy for your trials. Attendees will leave with actionable insights on how flexible, structured monitoring can:

  • Improve visibility into what’s been reviewed, by whom and why
  • Drive efficiency and consistency without rigidity
  • Enable better decision-making and prioritization across diverse study designs.

 

This session will provide you with a roadmap to bringing early phase studies into the RBQM fold.

TRI TRIALS

Powering Pragmatic Decentralised Trials with Real-World, Real-Time Data

  • Discover how routinely collected healthcare data can power the next generation of pragmatic and decentralised clinical trials.
  • Learn how integrating real-time electronic health record (EHR) data into trial workflows can accelerate recruitment and reduce burden on sites and patients.
  • Explore practical approaches for generating high-quality real-world evidence alongside traditional interventional study data.
  • Gain insight into the technology, governance, and operational partnerships required to deliver scalable, patient-centric research models in practice.

Europe at a Crossroads: Modern Clinical Trials, Market Pressures, and the UK’s approach in the global competitive environment

  • The traditional CRO model is no longer fit for purpose
    Transactional, vendor-based approaches create duplication, misalignment, and inefficiency, slowing trials precisely when regulatory systems are designed to move faster.
  • Integrated partnerships are the new execution engine for clinical trials
    Success in Europe now depends on deeply integrated CRO-biotech models with shared accountability, centralized oversight, and proactive regulatory strategy built in from the start.
  • Winning in 2026 requires a global, lifecycle-driven strategy
    Biotechs can combine different global solutions for early phase acceleration.

Unlocking UK trials through primary care: predictable, accurate and fast recruitment

UK clinical research faces a persistent challenge in translating study design into timely, predictable recruitment at scale. Ongoing variability in feasibility, slow start‑up and fragmented patient identification continue to affect delivery, site workload and participant experience.

In this presentation, Solutions Specialist Isabel Hunt will demonstrate how closer collaboration with primary care, underpinned by comprehensive, coded general practice data, can address these challenges end to end. Using the Recruit solution, embedded within the UK’s leading GP clinical systems, sponsors and CROs can enable predictable, accurate and fast recruitment through improved feasibility, faster identification of eligible patients and trusted GP‑led engagement at scale.

Attendees will learn how Recruit reduces time to first patient in, lowers screen failures, minimises site burden and supports more reliable trial delivery. The session will also explore how secure, consent driven primary care data supports ongoing study delivery and real‑world evidence generation across the UK.

INSPIRATIONAL KEYNOTE Clinical Operational Excellence: Delivery like an Elite Athlete

  • What is the Athlete Mindset?
  • Parallels between elite sport and clinical trial delivery
  • Applying the athlete-style discipline, goal-setting, ‘pivot quickly’ mindset and performance tracking in delivering complex oncology trials
  • Translating setbacks into learnings and future strengths- The drive for continuous improvement-The perfect race!
  • Sustaining performance and energy across multi-year clinical trials- The Long-Distance Athlete